Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43159
UPID:
RRP8_HUMAN
Alternative names:
Cerebral protein 1; Nucleomethylin
Alternative UPACC:
O43159; Q7KZ78; Q9BVM6
Background:
Ribosomal RNA-processing protein 8, also known as Cerebral protein 1 and Nucleomethylin, plays a pivotal role in the eNoSC complex, crucial for rDNA silencing in response to cellular energy levels. This process involves histone modifications, including H3 deacetylation and H3K9me2 dimethylation, leading to the formation of silent chromatin at the rDNA locus. RRP8's specific function within this complex includes binding to H3K9me2 and potentially acting as a methyltransferase.
Therapeutic significance:
Understanding the role of Ribosomal RNA-processing protein 8 could open doors to potential therapeutic strategies.